당뇨병 관리 : 혈당측정기 시장

※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

현재 전세계에 약 4억 2,500만명의 성인(20-79세) 당뇨병 환자가 있는데, 2045년에는 그 수가 6억 2,900만명까지 증가할 것으로 예측됩니다. 당뇨병 환자 건강 관리에 있어서 혈당측정기는 필수입니다. 세계 혈당측정기(BGMD) 시장 규모는 2018년에는 약 80억 달러, 2023년에는 130억 달러에 달하고, 약 11%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 고성능 제품 필요성과 잇따르는 기술 진보, 꾸준한 시장 규모(치료비) 확대 전망 등이 향후 시장 성장에 기여할 전망입니다. 한편, 가격 경쟁 심화와 시장 포화화, 저가 검사지와의 경쟁 등의 요인에 의해 시장 성장률이 하락할 가능성도 있습니다.

세계의 혈당측정기(Blood Glucose Monitoring Devices) 시장을 분석했으며, 질환 개요, 주요 출시 제품/파이프라인 제품, 주요 시장 성장 촉진요인 및 저해요인, 향후 시장 기회, 시장 규모 예측(향후 5년간), 시장 점유율 구조, 주요 기업 개요와 재무 분석, 성장 전략 등의 정보를 정리하여 전해드립니다.

주요 요약

제2장 질환 개요

• 환자수
• 당뇨병의 정의
  • 증상
  • 병존증
  • 진단 및 치료 방법
  • 당뇨병 비용
• 참고 문헌

제2장 혈당측정기

• 혈당측정기
  • Abbott
  • Ascensia Diabetes Care
  • LifeScan/Platinum Equity
  • Roche
  • Livongo
  • One Drop/Apple Watch
• 연속혈당측정기(CBM)
  • Abbott
  • Dexcom
  • Medtronic
• 신형 웨어러블 혈당 모니터링 제품
  • Medtronic: glucose-sensing patch
  • Nemaura Medical
  • Senseonics
  • Verily
• 당뇨병 모니터링용 모바일 앱
• 참고 문헌

제3장 시장 분석

• 혈당측정기 시장
  • 시장 예측 : 세계
  • 시장 예측 : 지역별/분야별
  • 미국 시장
  • 유럽 주요 5개국(EU5) 시장
  • 일본 시장
  • 기타 국가(RoW) 시장
  • 시장 성장 촉진요인 및 억제요인
• 경쟁 분석
  • 시장 점유율 : 세계 전체/종합 분석
  • 시장 점유율 : 분야별
  • 시장 점유율 : 지역별
• 기업 개요
  • Abbott
  • Ascensia Diabetes Care
  • Dexcom
  • Medtronic
  • Nemaura Medical
  • Roche
  • Senseonics
• 참고 문헌

부록 : 기업 리스트

Overview:

According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.

Blood glucose monitoring is essential for people with diabetes to lower the risk of complications. It is particularly important for those with type 1 diabetes, but also in people with type 2 diabetes who frequently administer insulin and/or suffer from symptomatic blood sugar fluctuations.

Blood glucose monitoring devices include both traditional handheld blood glucose meters (BGMs) used by patients at home and by healthcare practitioners at the point-of-care, and new sophisticated continuous glucose monitoring systems (CGMs) used by type 1 and insulin-dependent type 2 diabetics.

Valued at nearly $8bn in 2018, the global Blood Glucose Monitoring Devices (BGMDs) Market is growing at a fast pace-at a compound annual growth rate (CAGR) of approximately 11%-due to the phenomenal sales growth of new revolutionary CGMs, such as Abbott's FreeStyle Libre and Dexcom's G6 CGM. The market is expected to total nearly $13bn by 2023­. Growth of CGMs will be offset by a steady decline in the BGMs segment due to continued extreme price competition/downward pricing pressure, lowered test-strip reimbursement, and market saturation of lower-cost meters, among other factors.

The overall BGMDs market is being driven by several positive factors, including:

• strong demand for discreet, accurate CGM devices that provide convenient blood glucose monitoring 24/7 and eliminate frequent/cumbersome and painful fingersticks

• steadily increasing awareness and adoption of new, next-generation CGMs (by Abbott and Dexcom) driven by strong sales/marketing/advertising and physician referrals

• solid clinical outcomes due to the ability to improve the accuracy of insulin delivery and improve glycemic control or time-in-range (TIR) via continuous (24/7) glucose monitoring

• the ability to integrate lucrative CGM sensors into fast-growing next-generation hybrid closed-loop insulin pump systems (eg MiniMed 670G, Tandem's t:slim, and future pump systems; see below Insulin Pumps report)

• better patient awareness and physician understanding of glucose trends and impact of diet/medication/exercise/lifestyle factors due to the use of smartphone-driven digital health coaching apps, resulting in improved diabetes management

• ability to lower overall healthcare costs

• solid reimbursement

• low CGM market penetration (due to newness of technology), leaving much room for market growth in a large and expanding diabetes population

• sales of lucrative recurring CGM disposables (eg sensors) and accessories.

This comprehensive medical market and technology report provides:

• prevalence of diabetes

• BGM/CGM product portfolios and technical innovations

• product pipelines/emerging technologies/startups

• trends and opportunities

• market drivers and limiters

• market and competitive analysis-including 5-year global and regional market forecasts, global/regional market share (2018), company overview, financials, and strategic growth plans.

Markets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Market forecasts are for the 2018-23 time period.

Table of Contents

Executive Summary

• i. Diabetes overview
• ii. Blood glucose monitoring technology
• iii. Global blood glucose monitoring devices market
• iv. Competition
• v. Methodology
• vi. Bibliography

• Exhibit ES-1: Blood glucose monitoring device sales by product segment, combined market forecast ($m), 2018-23

1. Diabetes Overview

• 1.1. Prevalence
• 1.2. Diabetes defined
  • 1.2.1. Symptoms
  • 1.2.2. Complications
  • 1.2.3. Diagnosis and treatment
  • 1.2.4. Cost of diabetes
• 1.3. Bibliography

2. Blood Glucose Monitoring Devices

• 2.1. Blood glucose meters
  • 2.1.1. Abbott
  • 2.1.2. Ascensia Diabetes Care
  • 2.1.3. LifeScan/Platinum Equity
  • 2.1.4. Roche
  • 2.1.5. Livongo
  • 2.1.6. One Drop/Apple Watch
• 2.2. Continuous blood glucose monitoring systems
  • 2.2.1. Abbott
  • 2.2.2. Dexcom
  • 2.2.3. Medtronic
• 2.3. New or emerging wearable blood glucose monitoring patches
  • 2.3.1. Medtronic: glucose-sensing patch
  • 2.3.2. Nemaura Medical
  • 2.3.3. Senseonics
  • 2.3.4. Verily
• 2.4. Diabetes monitoring mobile apps
• 2.5. Bibliography

• Exhibit 2-1: Accuracy of blood glucose meters - top 8 with lowest MARD
• Exhibit 2-2: Selected blood glucose meter brands by manufacturer
• Exhibit 2-3: Selected blood glucose meters and features
• Exhibit 2-4: The FreeStyle Lite
• Exhibit 2-5: The Contour NEXT One and Contour Diabetes app
• Exhibit 2-6: The Contour NEXT Link 2.4
• Exhibit 2-7: OneTouch Verio Flex meter with OneTouch Reveal app and OneTouch Verio meter
• Exhibit 2-8: OneTouch Reveal Plus powered by Welldoc's BlueStar intelligent diabetes coaching technology
• Exhibit 2-9: Welldoc's BlueStar diabetes AI-driven smart app
• Exhibit 2-10: The new Accu-Chek Guide, Guide me, and mySugr app
• Exhibit 2-11: One Drop Mobile app, glucose meter/accessories, and the Apple Watch
• Exhibit 2-12: Selected continuous glucose monitoring systems by manufacturer
• Exhibit 2-13: Selected continuous glucose monitoring systems and features
• Exhibit 2-14: The FreeStyle Libre 14-day CGM System
• Exhibit 2-15: The LibreLink app
• Exhibit 2-16: The Dexcom G6 CGM System with extended 10-day sensor
• Exhibit 2-17: Dexcom CLARITY diabetes management software
• Exhibit 2-18: The Guardian Connect CGM System with Sugar.IQ app
• Exhibit 2-19: The iPro2 Professional CGM system with CareLink iPro software
• Exhibit 2-20: The SugarBEAT system
• Exhibit 2-21: How the SugarBEAT draws glucose from interstitial fluid
• Exhibit 2-22: Senseonic's Eversense Continuous Glucose Monitoring System and insertion procedure
• Exhibit 2-23: Verily Lifesciences' investigational glucose-measuring contact lens

3. Market Analysis

• 3.1. Blood glucose monitoring devices market
  • 3.1.1. Market forecast: global
  • 3.1.2. Market forecast: by region and segment
  • 3.1.3. US market
  • 3.1.4. Five major EU markets
  • 3.1.5. Japanese market
  • 3.1.6. Rest of the world market
  • 3.1.7. Market drivers and limiters
• 3.2. Competitive analysis
  • 3.2.1. Market share: global/combined
  • 3.2.2. Market share: by segment
  • 3.2.3. Market share: by region
• 3.3. Corporate profiles
  • 3.3.1. Abbott
  • 3.3.2. Ascensia Diabetes Care
  • 3.3.3. Dexcom
  • 3.3.4. Medtronic
  • 3.3.5. Nemaura Medical
  • 3.3.6. Roche
  • 3.3.7. Senseonics
• 3.4. Bibliography

• Exhibit 3-1: Blood glucose monitoring device sales by product segment, combined market forecast ($m), 2018-23
• Exhibit 3-2: Blood glucose monitoring devices market, forecast sales by region ($m), 2018-23
• Exhibit 3-3: Blood glucose monitoring device sales by product segment and region, combined market forecast ($m), 2018-23
• Exhibit 3-4: Combined blood glucose monitoring devices market, global share by supplier ($m), 2018
• Exhibit 3-5: Blood glucose meters market, global share by supplier ($m), 2018
• Exhibit 3-6: Continuous glucose monitoring systems market, global share by supplier ($m), 2018
• Exhibit 3-7: Combined blood glucose monitoring devices market, estimated share by supplier and region, 2018
• Exhibit 3-8: Abbott, revenues by segment, FY2018
• Exhibit 3-9: Dexcom, revenues by segment, FY2018
• Exhibit 3-10: Medtronic, revenues by segment, FY2019
• Exhibit 3-11: Roche, revenues by segment, FY2018
• Exhibit 3-12: Senseonics, revenues by segment, FY2018

Appendix A: company listing